Volume : 08, Issue : 06, June – 2021
Title:
33.A COMPREHENSIVE REVIEW ON CO-CRYSTALS
Authors :
P.M.M. Naga Lakshmi Varma*, M. Hemalatha, M.Jahnavi Sai, B.Dhana Lakshmi1, K.Kavitha, K.Hima Bindu, Dr.K.Padmalatha
Abstract :
Poor aqueous solubility and low oral bioavailability of an active pharmaceutical ingredient are the limitations during the growth of a new product. Co-crystal formation is a new approach to enhance the physicochemical properties of the active pharmaceutical ingredient. Co-crystallization with pharmaceutically acceptable compounds does not affect the pharmacological activity of the API but can improve the physical properties like solubility, stability and dissolution rate. Cocrystals are multi-component system of active pharmaceutical ingredient with a stoichiometric amount of a pharmaceutically acceptable coformer included within the crystal lattice. By manufacturing pharmaceutical co-crystals, the physicochemical properties of a drug can be improved thus it offers a great opportunity for the development of new drug products in the pharmaceutical industry. Most significantly, co-crystals can create new medicines with increased solubility and hence improve the efficiency and safety of the treatment. The main factor which affects co-crystal preparation is its thermodynamic stability. There are different methods used for the synthesis of co-crystal such as grinding, slurrying, antisolvent, hot-melt extrusion, spray drying, etc.
KEYWORDS: Pharmaceutical co-crystals, co-crystallization, Dissolution rate, solubility, stability, solvent evaporate
Cite This Article:
Please cite this article in press P.M.M. Naga Lakshmi Varma et al., A Comprehensive Review On Co-Crystals.., Indo Am. J. P. Sci, 2021; 08(06).
Number of Downloads : 10
References:
1. Ning Q., Mingzhong L., Walkria S., Nazneen M., Angela D., Gary T. Pharmaceutical co-crystalss- An overview, Int. J.Pharm., 2011, 419 (1), 1-11.
2. Desale PK.: Co-crystalslization is an a novel method, Int. J.Pharm. Invention, 2013, 3(1), 19-26.
3. Kumar S, Nanda A. Pharmaceutical cocrystals: an overview. Indian J. Pharm. Sci., 2018; 79(6):858-71.
4. Panzade P, Shendarkar G, Shaikh S, Rathi PB. Pharmaceutical Cocrystal of Piroxicam: Design,formulation and evaluation. Adv. Pharm. Bull, 2017; 7(3):399.
5. Ren S, Liu M, Hong C, Li G, Sun J, Wang J, et al. The effects of pH, surfactant, ion concentration, coformer, and molecular arrangement on the solubility behaviour of myricetin co-crystals. Acta Pharm. Sin. , 2019; 9(1): 59-73.
6. Lahamage S, Darekar A, Saudagar R. Pharmaceutical cocrystallization. Asian J. Res. Pharm.Sci., 2016; 6(1): 2231-5640.
7. Aher N, Shinkar D, Saudagar R. Pharmaceutical Cocrystallization: A Review. J Adv Pharm Edu Res, 2014; 4(4): 388-396.
8. Kotak U, Rajput V, Solanki H, Jani G, Jha P. Cocrystallization technique its rationale and recent progress, World J Pharma Pharma Sci, 2015; 4(4): 1484-1508.
9. Fukte SR, Wagh MP, Rawat S. Coformer selection: An important tool in co-crystal
10. Formation. Int J Pharm Sci, 2014; 6(7): 9-14.
11. Qiao N, Li M, Schlindwein W, Malek N, Davies A, Gary T. Pharmaceutical cocrystals: An overview. Int. J Pharm, 2011; 419(1-2): 1-11.
12. Gadade DD, Pekamwar SS. Pharmaceutical cocrystals: regulatory and strategic aspects,design and development. Adv. Pharm. Bull, 2016; 6(4): 479.
13. Panzade P, Shendarkar G. Design and Preparation of Zaltoprofen-Nicotinamide
a. Pharmaceutical Cocrystals via Liquid Assisted Grinding Method. Indian .Pharm. Educ. Res.,2019; 53(4): S563-70.
14. Kelly AL, Halsey SA, Bottom RA, Korde S, Gough T, Paradkar A. A novel transflectance near infrared spectroscopy technique for monitoring hot melt extrusion. Int. J. Pharm, 2015;496(1): 117-23.
15. Sanjay A, Manohar D, Bhanudas SR. Pharmaceutical cocrystallization: A review. J. Adv.Pharm, 2014; 4(4).
16. Aitipamula S, Vangala VR. X-ray crystallography and its role in understanding the physicochemical properties of pharmaceutical cocrystals. J Indian Inst Sci., 2017; 97(2): 227-43.
17. Patole T, Deshpande A. Co-crystallization-a technique for solubility enhancement. Int. J. Pharm. Sci. Res., 2014; 5(9): 3566-76.
18. Alatas FI, Ratih HE, Soewandhi SN. Enhancement of solubility and dissolution rate of telmisartan by telmisartan-oxalic acid cocrystal formation. Int. J. Pharm. Res., 2015; 7(3): 423-6.